Plagued by delays, AstraZeneca HQ costs soar to £750M as it edges toward 2020 completion
In the latest update on AstraZeneca’s delay-prone HQ project, the pharma giant revealed that the cost of construction has swelled to £750 million ($956 million) — more than double the original estimate in 2013.
The move-in date is still in 2020, a spokesperson confirmed, after AstraZeneca pushed projected completion from 2016 to 2017, and then to the spring of 2019. While the initial plan called for a £330 million (then $500 million) investment, the cost ballooned to £500 million ($650 million), and more in the most recent update.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.